Dr. Leone joined MUSC in 2017 as the Hollings Cancer Center Director from the Ohio State University Comprehensive Cancer Center. A Professor of Biochemistry & Molecular Biology, he also holds the Grace E. DeWolff Endowed Chair in Medical Oncology and serves as the Senior Associate Dean for Oncology in the College of Medicine. As Director, Dr. Leone will oversee the patient care arm of the Hollings Cancer Center as well as lead cancer-related research efforts in order to achieve and promote transdisciplinary and translational collaborative research. Dr. Leone’s research focuses on identifying how disruption of critical cell cycle regulatory pathways contributes to uncontrolled cell growth, a hallmark of cancer. He has authored more than 120 peer-reviewed publications and has received numerous recognitions for his contributions to cancer research.
Dr. Alberg has served as an Associate Director since 2006. A Professor of Public Health Sciences, he also holds the Blatt Ness Distinguished Endowed Chair in Oncology. In his role as Associate Director, he develops and implements initiatives to integrate the expertise in cancer population science across all areas of the Center and works to increase collaboration among the cancer control scientists at Hollings and the South Carolina Department of Health and Environmental Control to implement cancer-focused initiatives, including the State Cancer Plan.
Dr. Britten is Chief of the Division of Hematology/Oncology in the Department of Medicine at MUSC and holds the Charles Westfield Coker Distinguished Endowed Chair supported by the South Carolina SmartState® Center of Excellence in Gastrointestinal Malignancies. As Associate Director, she oversees the entire clinical research enterprise at Hollings. A nationally recognized Phase I clinical trials expert, she is charged with facilitating the efforts to bring scientific discoveries emanating from Hollings scientific laboratories into clinical application through clinical trials.
Dr. Diehl is a Professor in the Department of Biochemistry and Molecular Biology and holds the SmartState Chair in Lipidomics, Pathobiology and Therapy. In his role as Associate Director, Dr. Diehl is charged with identifying and shaping the trajectory of new scientific directions and integrating basic science discoveries across discipline areas while facilitating the application of these discoveries into the development of innovative preventative, diagnostic and therapeutic applications.
A Professor of Public Health Sciences, Dr. Ford oversees the Center’s effort to address the critical cancer disparities of South Carolina through community outreach and educational programs. Dr. Ford and her team work with minority leaders throughout the state to build bi-directional, trusting, and long-lasting partnerships, which are critical to Hollings investigators in tailoring culturally and contextually knowledgeable cancer interventions. She also develops and nurtures partnerships between Hollings and several South Carolina Historically Black Colleges and Universities to provide undergraduate minority students the opportunity to explore biomedical career options.
Dr. Lilly works to connect Hollings laboratory researchers with clinical investigators to promote bi-directional translational opportunities that will lead to improved strategies for prevention, diagnosis and treatment of cancer. A Professor of Medicine and medical oncologist focusing on genitourinary cancers, he also leads a nationally recognized physician scientist career development program at Hollings.
Dr. Mahvi serves as the Chief of the Oncology Integrated Center of Clinical Excellence (ICCE) and Chief of Surgical Oncology. In his leadership role, Dr. Mahvi oversees the clinical activities and performance of the Hollings Cancer Center. In coordination with MUSC leadership, faculty, physicians and staff, Dr. Mahvi executes strategies for program development, growth and patient access as well as managing the financial efforts of clinical operations.
Dr. Marshall is a Professor of Radiation Oncology. In his role at Hollings, he ensures the infrastructure supporting the clinical research is effective and efficient, and he ensures that patients and physicians have timely access to the latest novel therapies being offered through clinical trials.
Dr. Rosenzweig is a Professor of Cell & Molecular Pharmacology. As Associate Director, he oversees the ongoing evaluation, development and growth of Hollings-supported shared research resources. These shared facilities provide access to critical technologies, services and consultation that enhance scientific interaction and productivity of cancer center members.
Dr. Watson is a Professor of Pathology & Laboratory Medicine. As Associate Director, he ensures the education and training opportunities for pre- and post-doctoral students as well as junior faculty within the Hollings Cancer Center are well-structured, coordinated across multiple initiatives, effective, and promote transdisciplinary collaborations.